Pfizer 2015 Annual Report Download - page 127
Download and view the complete annual report
Please find page 127 of the 2015 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117 -
118 -
119 -
120 -
121 -
122 -
123 -
124 -
125 -
126 -
127 -
128 -
129 -
130 -
131 -
132 -
133 -
134
 |
 |
Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
126
2015 Financial Report
C. Other Revenue Information
Significant Customers
We sell our biopharmaceutical products primarily to customers in the wholesale sector. In 2015, sales to our three largest U.S. wholesaler
customers represented approximately 14%, 11% and 10% of total revenues, respectively, and, collectively, represented approximately 23% of
total trade accounts receivable as of December 31, 2015. In 2014, sales to our three largest U.S. wholesaler customers represented
approximately 13%, 10% and 9% of total revenues, respectively, and, collectively, represented approximately 25% of total trade accounts
receivable as of December 31, 2014. In 2013, sales to our three largest U.S. wholesaler customers represented approximately 12%, 9% and
8% of total revenues, respectively. For all years presented, these sales and related trade accounts receivable were concentrated in our
biopharmaceutical businesses.